[Skip to content]

Royal Brompton & Harefield NHS Foundation Trust
About the Trust
Search our Site
Hybrid theatre

Our work and hospitals

What we do

Royal Brompton & Harefield NHS Foundation Trust is the largest specialist heart and lung centre in the UK and among the largest in Europe. We work from two sites: 

  • Royal Brompton Hospital in Chelsea, West London
  • Harefield Hospital near Uxbridge.


The Trust is a partnership of these two specialist hospitals which are known throughout the world for their expertise, standard of care and research success. 

What is a specialist trust?

Specialist trusts treat patients with rare and complex conditions in a specific area of health. Their clinical teams are skilled in the development and early adoption of new therapies and techniques, and many of the  patients they care for  cannot be treated in general hospitals.

Specialist trusts are at the forefront of innovation in healthcare and are often responsible for breakthroughs in treatments, which are then adopted by the whole healthcare system. Clinical staff at specialist hospitals are experts in their chosen field and often relocate to specialist centres to further develop their skills. UK specialist trusts welcome clinical specialists from around the globe.

Royal Brompton & Harefield NHS Foundation Trust is a partnership of two specialist heart and lung hospitals, which means that we only provide treatment for people with heart and lung disease. We carry out some of the most complicated surgery, and offer some of the most sophisticated treatment that is available anywhere in the world

Among their many achievements, experts at the Trust:

  • pioneered intricate heart surgery for newborn infants born with a congenital heart disease
  • performed the first successful heart and lung transplant in Britain
  • implanted the first coronary stent
  • achieved a world first by implanting a Tendyne transcatheter mitral valve system to treat a leaking mitral heart valve.

Our research


Research programmes play a vital role at both our hospitals. This is because the most talented medical experts are rarely content with using tried and tested methods to treat their patients. 

The opportunity to influence the course of modern medicine by developing new treatments is a prospect that attracts them to specialist centres, where research opportunities are a fundamental part of delivering patient care. Many medical advances made at the Trust have been taken up across the NHS and beyond. 


Each year, between 500 and 600 papers by researchers associated with the Trust are published in peer-reviewed scientific journals, such as The Lancet and New England Journal of Medicine. 


Our main partner is the  National Heart and Lung Institute at Imperial College, London. We run additional research projects with other hospitals and universities in the UK and abroad. 

Useful facts


  • We are the leading UK provider of respiratory care and are national leaders in the specialist areas of paediatric cardiorespiratory care, congenital heart disease and cystic fibrosis. 


  • In 2016, we cared for around 200,000 patients in our outpatient clinics supervised around 40,000 inpatient stays. 


  • We are one of the country's largest centre for the treatment of congenital heart disease, treating both children and adults. Our clinical teams treat more than 10,000 patients with these diseases each year  and many receive care from their first few days of life through to adulthood.


  • Our heart attack centre at Harefield has pioneered the use of primary angioplasty for the treatment of heart attacks and has one of the fastest treatment times in the country at only 27 minutes, compared to the national average of 42, a crucial factor in patients' survival. 


  • Our on-site fetal cardiology service enables clinicians to begin caring for babies while still in the womb; some are scanned  and diagnosed at just 12 weeks, when the heart measures just over a millimetre.


  • One of Europe's largest units for the treatment of cystic fibrosis is based at Royal Brompton Hospital: we see nearly 700 patients with the condition.

  • In 2016, we recruited around 4,500 patients to research studies.


European Society of Cardiology highlights pioneering research and patient care at Royal Brompton Hospital

Cath lab
"We believe we can give the best care to our patients by having a high-profile interaction between our clinical and research colleagues."

Read the full article.